Economic Evaluation of Diagnosis Tuberculosis in Hospital Setting by Scherer, Luciene C.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 19
Economic Evaluation of
Diagnosis Tuberculosis in Hospital Setting
Luciene C. Scherer
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/54479
1. Introduction
Tuberculosis (TB) is an ancient disease, but not a disease of the past. After disappearing
from the world public health agenda in the 1960s and 1970s, TB returned in the early 1990s
for several reasons, including the emergence of the HIV/AIDS pandemic and the increase in
drug resistance. More than 100 years after the discovery of the tubercle bacillus by Robert
Koch, what is the status of TB control worldwide? The evolution of global TB control poli‐
cies, including DOTS (Directly Observed Therapy, Short course) and the Stop TB Strategy,
and assess whether the challenges and obstacles faced by the public health community
worldwide in developing and implementing this strategy can aid future action towards the
elimination of TB.(Lienhardt, Glaziou et al. 2012) The report of the Commission on Macro‐
economics and Health of the World Health Organization has emphasized that tuberculosis
is the most common of the infectious diseases. Tuberculosis is one of the most important
health problems in the world, causing 1.4 million deaths each year, in 2011. (WHO, 2010)
The most of TB cases (82%) was concentrated in 22 countries around the world. In the year
of 2010, in Brazil were detected 81946 cases, with 5000 death (WHO, 2010).
In Rio Grande do Sul, a state in extreme south of Brazil, the incidence of TB in 2011 was 46,1
per 100.000, with 4947 new cases. Porto Alegre, capital of Rio Grande do Sul shows inci‐
dence of 116 in 2009.(Sul 2011; Brazil 2012)
Tuberculosis is the first cause of death in patients with AIDS in Brazil. Patients with co-in‐
fection HIV/TB have had in treatment of Tuberculosis probability of worst outcome.
Rio Grande do Sul, has had the major incidence of TB/HIV co-infection. The co-infection
adversely affects the lives of individuals in both the biological and psychosocial aspects.
(Neves, Canini et al. 2012)
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Some factors can be considered as risk factors for co-infection of TB and HIV, as the im‐
poverishment of the population, use of injecting drugs, the disruption of services on the
epidemiology of  TB control,  the  delay  in  the  diagnosis  of  TB and increased risk  of  ac‐
quiring multi-drug resistant  TB (MDRTB),  essentially  associated to the expansion of  the
disease  in  the  world.(Kritski,  Lapa  e  Silva  et  al.  1998).  Multidrug-resistant  tuberculosis
(MDR-TB) is a major clinical challenge, particularly in patients with human immunodefi‐
ciency  virus  (HIV)  co-infection.(Nathanson,  Nunn et  al.  ;  Farley,  Ram et  al.  2011;  Arjo‐
mandzadegan, Titov et al. 2012; Jain, Dixit et al. 2012; Udwadia 2012)
For the above, in recent years became consensus that the epidemic of TB in developing
countries demands the evaluation of broader approaches, described in the Plan STOP-
TB/OMS control global TB 2006-2015.
Among them have been prioritizing the implementation of:
a) improvements in access to diagnostic system user health; b) culture for mycobacteria in
every patient suspected of TB and HIV positive and all TB patients in retreatment; c) sensi‐
tivity test for suspected cases of resistant TB (retreatment cases, treatment failure, contact
MDR-TB or have been treated at the Health Unit with a high rate TB-MDR/XDR); d) review
and economic evaluation under routine conditions of deployment of new technologies (phe‐
notypic or molecular, automated or not) for the early diagnosis of TB, resistant TB patients
with paucibacillary TB, HIV-infected or suspected drug-resistant TB.
Early detection of tuberculosis (TB) is essential for infection control. Rapid clinical diagnosis
is more challenging in patients who have co-morbidities, such as Human Immunodeficiency
Virus (HIV) infection. Direct microscopy has low sensitivity and culture takes 3 to 6 weeks
(Sharma, Mohan et al. 2005; WHO 2006). Diagnostic testing for tuberculosis has remained
unchanged for nearly a century, but newer technologies hold promise for a revolution in tu‐
berculosis diagnostics. Tests such as the nucleic acid amplification assays commercial and in
house technologies allow more rapid and accurate diagnosis of pulmonary and extrapulmo‐
nary tuberculosis.(Rodrigues Vde, Queiroz Mello et al. 2002; Sanchez, Rossetti et al. 2006;
Scherer, Sperhacke et al. 2007; Scherer, Sperhacke et al. 2011; Hida, Hisada et al. 2012). Xpert
MTB/RIF (Xpert) is actually a promising new rapid diagnostic technology for tuberculosis
(TB) which has characteristics that suggests large-scale roll-out.(Vassall, van Kampen et al.
2011). In developing countries, in house Polymerase Rhain reaction (PCR) based on amplify‐
ing the IS6110 insertion element can be used for the amplification of Mycobacterium tuberculo‐
sis (MTB) DNA and offers the potential of a sensitive, specific and rapid diagnostic for
ruling out or considering pulmonary tuberculosis (PTB) (Mehrotra, Metz et al. 2002; Sar‐
miento, Weigle et al. 2003; Schijman, Losso et al. 2004; Flores, Pai et al. 2005).
The appropriate and affordable use of any of these tests depends on the setting in which
they are employed (Perkins 2000; Brodie and Schluger 2005). New tools for TB diagnosis,
treatment and control are necessary, especially in health settings with a high prevalence of
HIV/TB co-infection.
Although TB is  one the greatest  causes of  mortality worldwide,  its  economic effects  are
not  well  known,  especially  in  Brazil.  Despite  the  fact  that  the  families  did  not  have  to
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pay  for  medications  and  treatment,  given  that  this  service  is  offered  by  the  State,  the
costs to families related to loss of income due to the disease were very high. The propor‐
tion of  public  service  funds utilized for  prevention is  small.  Greater  investment  in  pre‐
vention campaigns not only might diminish the numbers of cases but also might lead to
earlier  diagnosis,  thus reducing the costs associated with hospitalization.  The lack of  an
integrated cost accounting system makes it  impossible to visualize costs across the vari‐
ous sectors.(Costa, Santos et al. 2005)
To make rational decisions about the implementation of new tools in the medical routine,
cost-effectiveness studies are essential(Mitarai, Kurashima et al. 2001; Kivihya-Ndugga, van
Cleeff et al. 2003; Hazbon 2004).
A key step in cost-effectiveness analysis is to identify and value cost. The economic concept
of opportunity cost is central to cost-effectiveness analysis. When a public health agency
spends money to provide health care, this money is not available for housing, education,
highway construction, or as a reduction in income taxes. When a health care organization
spends money for bone transplantation, this money is not available for example for mam‐
mography outreach or something. When an elderly man spends time being vaccinated for
influenza, this time is not available to play golf or to work. An overall conceptual goal in
cost-effectiveness analysis is comprehensive identification of all costs of the intervention and
its alternative, including all of the opportunity costs.
Contributors to cost must be identified before the costs can be valued. The terms used to de‐
scribe the contributors to cost (e.g. direct costs, indirected costs, opportunity costs) are used
in different ways in different textbooks and in published cost-effectiveness analysis.
The definition of cost terms is the opportunity cost is the value of resources in an alter‐
native  use,  the  direct  cost  is  the  value  of  all  goods,  services,  and  other  resources  con‐
sumed  in  the  provision  of  an  intervation  or  in  dealing  with  the  side  effects  or  other
current and future consequence linked to it and the productivity costs are the costs asso‐
ciated with lost  or impaired ability to work or engage in leisure activities  and lost  eco‐
nomic  productivity  due  to  death  attributable  to  the  disease.  These  costs  have  been
substituted for indirect costs. There are several categories of direct costs. The first catego‐
ry of  total  direct  cost  is  direct  health cost,  this  category include costs  with tests,  drugs,
supplies,  personnel,  equipment,  rent,  depreciation,  utilities,  maintenance  and  support
services. The second category of total direct cost is direct non- health care cost, these cost
include  for  example  the  cost  to  patients  to  partake  of  the  intervention  e.g.,  transporta‐
tion,  child  care,  parking).  The  third  category  of  total  direct  cost  is  the  cost  of  informal
caregiver  time,  this  is  the monetary value of  the time of  family members  or  volunteers
who provide home care. The fourth category of total direct cost is the cost is the cost of
the  use  of  patient  time.  Such  studies  provide  insight  into  the  composition  of  different
cost  components,  which  may  be  the  most  important  factor  from  the  patient  and  the
health  service’s  perspectives.  Recent  studies  have  compared  the  cost  effectiveness  of
news tools for diagnosis,  treatment and control  in Tuberculosis.(Amicosante,  Ciccozzi  et
al.  ;  Kowada, Deshpande et al.  ;  Baltussen, Floyd et al.  2005; Barbieri,  Wong et al.  2005;
Bachmann 2006; Dwolatzky, Trengove et al.  2006; Kominski,  Varon et al.  2007; Kowada,
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Takahashi  et  al.  2008;  Rosen,  Taylor  et  al.  2010;  Shi,  Hodges  et  al.  2010;  Vassall,  van
Kampen et al. 2011; Fitzpatrick and Floyd 2012; Lienhardt, Raviglione et al. 2012; Manda‐
lakas, Hesseling et al.  2012).  In a recent study we compared the cost-effectiveness of di‐
rect  microscopy by Ziehl  Neelsen staining (AFB smear)  with  in  house  polymerase  chain
reaction (PCR) and with culture on the first  sputum specimen collection,  including staff
costs, using culture and clinical evaluation as the gold standard (Scherer, Sperhacke et al.
2009). In contrast to the cost-effectiveness analysis described by van Cleef et al.  in a ref‐
erence ambulatory clinic in Kenya, where only culture for mycobacteria was used as the
gold standard (Roos, van Cleeff et al. 1998; van Cleeff, Kivihya-Ndugga et al. 2005). The
cost-effectiveness of the AFB smear plus PCR dot-blot strategy described in recent study
was similar to other strategies, when lower TB prevalence made PCR more expensive for
diagnosis  of  PTB (Roos,  van Cleeff  et  al.  1998;  van Cleeff,  Kivihya-Ndugga et  al.  2005).
(Scherer et. aL., 2009).
The mathematical models may be particularly useful for predicting the long term tenden‐
cy of occurrence of the infection or disease. These models can simulate situations epide‐
miological  and  preventive  or  curative  interventions  beyond  their  theoretical  impact  in
reducing the problem. Such predictive models properly formulated and fed with consis‐
tent  data,  may assist  the  processes  of  planning and management  in  public  health.  Cur‐
rently  several  strategies  have allowed the use  of  Multiple  Logistic  Regression (MLR) in
the construction of predictive models. Models of decisions trees are also used for classifi‐
cation decision making or to provide a decision algorithm for the clinical management of
infectious diseases.(Aguiar, Almeida et al. 2012)
For developing countries, the emergence of continuous technological innovation represents
a double burden. The rapid diffusion of scientific and technical information that are ob‐
served now and monetary action multinational companies create a local demand for innova‐
tion by health professionals, the media and more informed portions of the population,
which further strains the health care system.
Many factors  limit  the  realization of  a  health  technology assessment  (HTA) analysis,  as
the lack of human resources, infrastructure or budget or due to lack of evidence or infor‐
mation costs.
Another obvious problem is that often decisions are based on scientific evidence coming
from developed countries and often in settings where the incidence of disease differs effu‐
sively of Brazilian and Latin American scenario.
Given this  scenario  health  managers  are  often between two objectives:  they have to  in‐
corporate new and more costly technologies to improve the health of the population and
at the same time are responsible for the financial sustainability and access equity of this
in the system health.(Project 2005)
Beyond the suffering caused directly by the disease, TB is requiring significant portions of
the public budget in developing countries. It is estimated that by 2015 they will be required
investments around $12 billion for control of diseases such as AIDS, TB and Malaria. The
increased costs involved in care and control of TB are due also to the increasing number of
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cases of resistant bacteria to different types of chemotherapy. (Polansky, Dymer et al. 1968;
Garcia Rodriguez, Marino Callejo et al. 1994; Weis, Foresman et al. 1999; Gomes, Soares et al.
2003; Elamin, Ibrahim et al. 2008; Kik, Olthof et al. 2009; Steffen, Menzies et al. 2010; Vassall,
Seme et al. 2010; Pereira, Barreto et al. 2012)
Costs of TB diagnosis and treatment may represent a significant burden for the poor and for
the health system in resource-poor countries. Costs incurred by TB patients are high in Rio
de Janeiro, especially for those under DOT. The DOT strategy doubles patients' costs and in‐
creases by fourfold the health system costs per completed treatment. The additional costs for
DOT may be one of the contributing factors to the completion rates below the targeted 85%
recommended by WHO (Steffen, Menzies et al. 2010).
Even in a country with a good health insurance system that covers medication and con‐
sultation costs, patients do have substantial extra expenditures. Furthermore, our patients
lost on average 2.7 months of productive days. TB patients are economically vulnerable.
(Kik, Olthof et al. 2009)
In Brazil, the real costs of TB are estimated or poorly known and the overall costs of TB are
not perceived by governments, given the fragmentation in the involvement of the three gov‐
ernmental levels: local, state and national.
The purpose of this chapter is to describe the direct and indirect costs for diagnosis and
treatment of Pulmonary Tuberculosis in patients infected or not by HIV, admitted to a Hos‐
pital Unit of Public Health.
2. Costs of health system of Brazil
In order to describe the costs of Health system of Brazil, we evaluate the costs directs of di‐
agnosis and treatment of screening of 1000 hypothetical patients suspects of Pulmonary Tu‐
berculosis in according with clinical and laboratory Brazilian recommendations for
treatment (Tuberculose 2004; Conde, Melo et al. 2009).
The cost components for each clinical and laboratory procedures of screening included costs
incurred by the patient, laboratory costs, drugs, consumables and equipment costs. The
strategy for screening was the same recommended for Brazilian Public Health System.
Clinical, radiological and laboratory staff costs were calculated from the salary base of Rio
Grande do Sul (State of Extreme South of Brazi) in 2011.
For each procedure, costs were attributed based on procedure costs of the Brazilian Public
Health System.
Running costs (material costs were used for each 1000 tests evaluated) included all laborato‐
ry materials used in procedures.
All costs were expressed in US$, using an exchange rate of US$ 1= R$ 1,72 (REAIS), the aver‐
age exchange rate from 2010 to 2011. In the treatment costs, those were evaluated related to
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the treatment of inpatients and outpatients. To estimate the values that are spent by the pub‐
lic health system of Brazil with the monitoring and control of TB in a hospital and an outpa‐
tient unit, we simulated two different scenarios:
a. TB cases diagnosed in hospital wards (hospitalized patients)
b. TB cases diagnosed in outpatient environment (outpatients).
The number of days considered to calculate the costs related to the treatment of inpatients
they were considered as the same days that were spent in laboratory procedure.
It was hypothesized that the time to detect Mycobacterium tuberculosis in sputum culture
from patients with pulmonary tuberculosis may be a better indicator for the duration of time
of hospitalization(Ritchie, Harrison et al. 2007).
The time to detect M. tuberculosis in the culture was 30 days in this study. This cohort is the
same as previous published by our group [20]. This value was used as the standard at which
release from isolation could be permitted (Scherer, Sperhacke et al. 2007)
The time spent on laboratory procedure to provide access to the result of the laboratory
technique was assumed to be 30 days for AFB smear plus culture. The number of days con‐
sidered to calculate costs was the same as those spent on laboratory procedure. The number
of days considered to calculate the cost of patient travel costs was assumed to be 2 days for
AFB smear plus culture.
Total treatment included clinical officer and hospital costs, assuming cost per pill, to be US$
0.22, using 3 pills per day, during 180 days; hospital room costs, US$ 7/day; costs with salary
of clinical staff and clinical consultation, US$ 2.52 per patient and clinical nursing consulta‐
tion, US$ 2.52 per patient.
Assuming that, during the treatment (6 months), in ambulatory situation, 6 AFB smear test,
6 chest radiographs, 6 consult of nurse and 2 consult of clinical were performed, we used
this parameters to estimate the costs of ambulatory following the Brazilian recommenda‐
tions for treatment (Tuberculose 2004).
Assuming  that,  during  the  hospitalization  (30  days),  4  AFB  smear  tests,  4  chest  radio‐
graphs, 30 nurse and physician consultations were performed, we used these parameters
to  estimate  the  costs  of  inpatient  assistance  in  hospital,  following  the  Brazilian  recom‐
mendations  for  treatment  (Tuberculose  2004;  Conde,  Melo  et  al.  2009).  Staff  salaries  for
the physician, nurse and radiologist were considered to be US$ 11,163 per year, and for
the chest radiograph technician, the salary was US$ 4,988 per year. The work days were
considered 20 days for all staff.
The days of admission to the hospital were considered to be the same number of days spent
on each laboratory procedure. All estimated costs reflect an estimative of the public health
system of Brazil expenses with the monitoring and control of TB.
The costs were expressed per 1000 suspects, according to the specific bibliographic refer‐
ences for economic analyses, thus, allowing the best decision for investment to be made
(Petitti 2000).
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Table 1A shows the costs at the health service level and Table 1B shows costs due to labora‐
tory investment. The AFB smear plus Culture require (US$ 39,535) for equipment. Table 1C
shows costs incurred by patients.
A. Health service costs
Staff
Number
Salaries of all staff
per year
(US$)
Staff Cost per day
(US$)
Time spent until access
to result
(days)
AFB smear plus
Culture 2 16,151 67 30
B. Laboratory costs
Equipment
(US$)
Annualization
Years
Running costs per 1000
suspects
(US$)
Running costs per
examination
(US$)
AFB smear plus
Culturea 39,535 5 12,507 12.50
C. Estimated costs incurred by patients, including costs for travel, food and income lossd
AFB smear plus Culture
(US$)
(outpatients and inpatients)
Travel 1,390
Food 10,000
Income Lossc 310,000
Total patients Cost 341,000
a Microscopic and Laminar Flow Cabinets,;. Other equipments were not included,
b Income loss of patients was calculated from monthly salary base of Brazil (US$207) and was based on proportional
days spent by patients until access to the result of each laboratory procedure. Patient costs were estimated using the
average of two visits to the laboratory for AFB smear and culture procedures for outpatients; Travel cost was consid‐
ered as US$ 1.4 (one bus ticket ). Food was considered as US$ 10 per meal. Base salary in Brazil was considered (US$ 10
per day /20 days of the work). For inpatients was considered just income loss; Staff costs in the laboratory were based
on proportional days spent on each laboratory procedure; Costs of consumables and equipment were provided by the
program as well as by the manufacturer.
Table 1. Estimative of Costs in US$ in Tuberculosis Diagnosis in Brazil
We annualized the capital cost of the equipment for 5 years, according to the literature [25].
Building costs were not included. Opportunity costs were not applicable.
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AFB smear plus Culture
Laboratory Costs
Labor Costsa 3,743
Investment costs 37
Running costs 3,700
Staff Costs per day
Cost laboratory staff b 1,434
Cost of staff related to the treatment of patientsb 2,791
Costs of chest radiograph staff related to the treatment of
patients 404
Treatment Costs per day
Costs of diagnostic service related to the treatment of no-
hospitalized patients 2,771
Costs of diagnostic service related to the treatment of hospitalized
patients 4,686
Treatment costs ( hospitalized patients plus no- hospitalized
patients)c 7,456
Income Loss 190,000
Total Patient costs 190,000
Total Health Service costs 9,479,033
Total Screening costs 9,668,815
a For each procedure, costs were attributed based on procedure costs of the Brazilian Public Health System (US$ 1,4 for
AFB smear and US$ 1,9 for Culture) and from CDCT/FEPPS (US$ 11,7 for PCR dot-blot), assuming investment laborato‐
ry equipment for 5 years; bStaff salary was considered; for laboratory technician, US$2,860 per year; for Laboratory
technologist, US$6,400 per year. Staff costs in the laboratory were based on proportional days spent on each laborato‐
ry procedure; Staff salary was considered for clinical physician, nurse and radiologist; US$6,400 per year; for the X-RAY
technician, salary was US$2,860 per year. cThe days of admission to the hospital were considered as the same as the
days spent on each laboratory procedure. The time spent on each laboratory procedure until access to the result of the
laboratory technique was assumed to be 30 days for AFB smear plus Culture. Total treatment included clinical officer
and hospital costs, assuming US$ 0,22 cost per pill, using 3 pills for day, during 180 days; hospital room costs, US$
4,16/day; costs of salary of staff clinical; clinical consultation cost, US$2,52 per patient; clinical nursing consultation, US
$2,52 per patient. Assuming that during the treatment of inpatients (4 months) 4 ZN and 4 chest radiograph were
performed, and during the treatment of no- hospitalized patients (6 months) 6 AFB smear and 6 chest radiograph
were performed, following the Brazilian recommendations for treatment (Tuberculose 2004);
d Travel was considered 2 days for AFB smear plus Culture strategy. Food and income loss for AFB smear plus Culture
strategy was considered 30 days
The health service costs analysis was based on processing 50 AFB smear slides and 14 cultures per day. AFB smear plus
Culture was performed by two trained staff.
Running costs were calculated from investments required to examine 1000 smears.
Table 2. Total cost of screening for 1000 suspects. The total screening costs to AFB smear plus Culture were US$
9,668.815.
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The total cost (in US$) related to the treatment (no hospitalized patients) for AFB smear plus
Culture was US$ 2,771. The cost related to the treatment of hospitalized patients, for AFB smear
plus Culture strategy was US$ 4,686. The cost related to the treatment of (no hospitalized pa‐
tients) and (hospitalized patients), for AFB smear plus Culture strategy was US$ 7,456.
However, in a context of advanced technologies for the diagnosis of tuberculosis, economic
resources has always limited the incorporation and diffusion of new technologies produced
and validated by the academy. It is a challenge for health systems worldwide, and in many
cases, the cause of serious sustainability problems.(Taylor, Drummond et al. 2004; King,
Griffin et al. 2006; Mason, Weatherly et al. 2007; Hughes, Tilson et al. 2009; Weatherly,
Drummond et al. 2009; Shi, Hodges et al. 2010)
The decisions related to incorporation, acquisition, reimbursement or coverage of new tech‐
nologies and those that determine the way in which they should be used are the most im‐
portant in the health system and should be taken in general and the management of health
services in particular.(Greenberg, Peterburg et al. 2005)
The health systems of different countries are diverse with respect to decisions about incor‐
porating technologies and expectations of service users. Tough choices are faced by manag‐
ers at all levels of the health system. This reality makes the TB every year, become more
difficult for the system to provide the user with the most effective intervention theoretically
available, depending on the pressures placed on the health system in relation to increased
costs, the training of human resources, needs updating certification and regulatory instru‐
ments, and investment in physical infrastructure (Newhouse 1992)
Attempts to improve the acceptability of resource allocation decisions around new health
technologies have spanned many years, fields and disciplines. Various theories of decision
making have been tested and methods piloted, but, despite their availability, evidence of
sustained uptake is limited. Since the challenge of determining which of many technologies
to fund is one that healthcare systems have faced since their inception, an analysis of actual
processes, criticisms confronted and approaches used to manage them may serve to guide
the development of an 'evidence-informed' decision-making framework for improving the
acceptability of decisions.(Stafinski, Menon et al. 2011)
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